In patients with driver-negative advanced or metastatic NSCLC, female patients exhibited a robust objective response rate to first-line combination anti-PD-1 therapy with chemotherapy than men, with greater progression-free survival and overall survival as well [63] (Table 2). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.